Teva Earns Investment-Grade Rating as Growth Strategy Advances
TEL AVIV, Israel, August 11, 2026 Teva Pharmaceutical Industries Ltd. announced that Moody’s Ratings has upgraded the company’s corporate...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
TEL AVIV, Israel, August 11, 2026 Teva Pharmaceutical Industries Ltd. announced that Moody’s Ratings has upgraded the company’s corporate...
Bridgewater, N.J., August 10, 2026 Grifols announced the completion of patient follow-up in SPARTA, its Phase 3 outcomes study...
Bridgewater, N.J., August 10, 2026 Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC, creating a scaled,...
ROME & CORAL GABLES, Fla., July 16, 2026 Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, marking a...
LEVERKUSEN, Germany, July 10, 2026 Bayer AG has announced a landmark €3.0 billion equity investment agreement with global asset...
PLAINSBORO, New Jersey, USA / BAGSVÆRD, Denmark, July 11, 2026 Novo Nordisk has announced positive long-term Phase 3 results...
SILVER SPRING, Maryland, July 10, 2026 The U.S. Food and Drug Administration (FDA) has proposed a new rule designed...
BOCA RATON, Fla., June 19, 2026 5W AI Communications has released its Pharma / Rx AI Visibility Index 2026,...
MUMBAI, India & NAPLES, Florida, USA, June 3, 2026 Lupin Limited and its alliance partner Natco Pharma have announced...
London, United Kingdom, May 25, 2026 The global market for CGRP inhibitors, one of the fastest-growing classes of migraine...
